Allstate Corp Has $224,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Allstate Corp decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 8.8% during the 1st quarter, Holdings Channel.com reports. The firm owned 906 shares of the medical instruments supplier’s stock after selling 87 shares during the period. Allstate Corp’s holdings in Becton, Dickinson and Company were worth $224,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in BDX. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $27,000. OLD Point Trust & Financial Services N A acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth approximately $29,000. DiNuzzo Private Wealth Inc. acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth approximately $30,000. Scarborough Advisors LLC acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth approximately $32,000. Finally, Fortitude Family Office LLC acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth approximately $35,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on BDX. Citigroup reduced their price target on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target on the stock. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Monday, July 15th. Barclays increased their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. Finally, Evercore ISI reduced their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $280.14.

Becton, Dickinson and Company Price Performance

Shares of BDX stock traded up $0.35 during trading hours on Monday, reaching $231.09. The company’s stock had a trading volume of 866,733 shares, compared to its average volume of 1,427,038. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $287.32. The company has a market capitalization of $66.79 billion, a price-to-earnings ratio of 50.86, a PEG ratio of 2.02 and a beta of 0.42. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.62. The firm’s 50 day simple moving average is $232.42 and its 200-day simple moving average is $236.40.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The company had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same period in the prior year, the company earned $2.86 EPS. Becton, Dickinson and Company’s revenue was up 4.6% compared to the same quarter last year. Sell-side analysts forecast that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Monday, June 10th were paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.64%. The ex-dividend date of this dividend was Monday, June 10th. Becton, Dickinson and Company’s payout ratio is 83.70%.

Insider Activity

In other news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, SVP Thomas J. Spoerel sold 300 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the transaction, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,615 shares of company stock worth $2,033,381. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.